Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-Up

At the AUA 2024 Annual Meeting, Vikram M. Narayan, MD, of Emory University School of Medicine, breaks down the presented 5-year follow-up data on the efficacy of intravesical nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.

He summarizes what this data suggests for patient care, whether there were any new safety signals or treatment-related grade 4/5 adverse events found, and upcoming trials to further investigate nadofaragene firadenovec in NMIBC, including ABLE-42.

View Dr. Narayan’s next comments on Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene Firadenovec in BCG-Unresponsive NMIBC.